Hydrogen sulphide compounds
The application describes Hydrogen Sulphide (H 2 S), or a (H 2 S) generating compound or compound capable of stimulating H 2 S production in a pregnant subject, for use in the treatment of pre-eclampsia (PE) or fetal growth restriction.
1. A method for treating pre-eclampsia or fetal growth restriction in a host animal, the method comprising (a) measuring an amount of H 2 S in a sample from the host animal; and (b) administering a therapeutically effective amount of a compound capable of generating hydrogen sulfide to the host animal.
2. The method of claim 1 wherein the compound is ACS14, ACS583, ACS84, ACS85, ACS86, DATS (diallyl trisulfide), S-diclofenac, sulfane, sulfur, thiocysteine, GSH hydropersulfide, GYY4137, SG1002, a H 2 S-donating derivative of sildenafil, ADT-OH, TBZ, 4-hydroxyphenyl isothiocyanate, thioglycine, 1-thiolysine, 1-thiovaline, H 2 S-Sartans, or H 2 S-L-DOPA or a salt of any of the foregoing, or a combination of any of the foregoing.
3. The method of claim 1 comprising administering GYY4137.
4. The method of claim 3 for treating pre-eclampsia.
5. The method of claim 3 for treating fetal growth restriction.
6. The method of claim 1 wherein the compound is ACS14, ACS583, ACS84, ACS85, or ACS86, or a salt of any of the foregoing, or a combination of any of the foregoing.
7. The method of claim 6 for treating pre-eclampsia.
8. The method of claim 6 for treating fetal growth restriction.
9. The method of claim 1 comprising measuring the amount of H 2 S in a sample of blood, serum, or plasma from the host.
10. The method of claim 1 comprising administering ACS14 or ADT-OH or a salt thereof.
11. The method of claim 10 for treating pre-eclampsia.
12. The method of claim 10 for treating fetal growth restriction.
13. The method of claim 11 comprising administering ACS14.
14. The method of claim 12 comprising administering ACS14.
15. The method of claim 1 wherein the amount of H 2 S is measured from CSE expression.
16. The method of claim 1 wherein the amount of H 2 S is measured from sFlt-1 expression.
17. The method of claim 1 wherein the amount of H 2 S is measured from PlGF production.
18. The method of claim 1 wherein the amount of H 2 S is measured from sEng production.
19. The method of claim 1 wherein the amount of H 2 S is measured from inhibition level of VEGF.
20. The method of claim 1 wherein the amount of H 2 S is measured from inhibition level of PlGF.